CombiMatrix 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	8-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	CombiMatrix Corp
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		12,680,927
Amendment Flag	FALSE
Entity Central Index Key	1383183
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Consolidated_Balance_Sheets_Cu

Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$6,734	$1,010
Short-term investments	1,996	4,230
Accounts receivable, net of allowance for doubtful accounts of $238 and $241	2,268	2,133
Supplies	345	367
Prepaid expenses and other assets	222	181
Total current assets	11,565	7,921
Property and equipment, net	832	584
Investments in unconsolidated subsidiaries and other	127	127
Total assets	12,524	8,632
Current liabilities:
Accounts payable, accrued expenses and other	1,644	1,107
Current portion, long-term debt	186	172
Total current liabilities	1,830	1,279
Capital lease obligations, net of current portion	95	82
Secured promissory note payable, net of current portion	123	151
Deferred rent	184
Total liabilities	2,232	1,512
Commitments and contingencies (Note 7)	0	0
Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5 million shares authorized; Series E - 2,202 shares authorized; 2,201.493 and none issued and outstanding	0	0
Common stock; $0.001 par value; 25 million shares authorized; 12,680,927 and 11,063,246 shares issued and outstanding	13	11
Additional paid-in capital	102,080	96,259
Accumulated other comprehensive income (loss)	1	-3
Accumulated net loss	-91,802	-89,147
Total stockholders' equity	10,292	7,120
Total liabilities and stockholders' equity	$12,524	$8,632

Consolidated_Balance_Sheets_Cu1

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts (in Dollars)	$238	$241
Convertible preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock; shares authorized	5,000,000	5,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	12,680,927	11,063,246
Common stock, shares outstanding	12,680,927	11,063,246
Series E Convertivle Preferred Stock [Member]
Preferred stock; shares authorized	2,202,000,000	2,202,000,000
Convertible preferred stock, shares issued	2,201	0
Convertible preferred stock, shares outstanding	2,201	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Royalties	$42	$32
Total revenues	2,329	1,822
Operating expenses:
Cost of services	1,230	998
Research and development	157	134
Sales and marketing	1,190	886
General and administrative	1,475	1,757
Patent amortization and royalties	25	32
Total operating expenses	4,077	3,807
Operating loss	-1,748	-1,985
Other income (expense):
Interest income	3	5
Interest expense	-20	-16
Total other income (expense)	-17	-11
Net loss	-1,765	-1,996
Net loss attributable to common stockholders	-2,655	-1,996
Basic and diluted net loss per share (in Dollars per share)	($0.15)	($0.18)
Basic and diluted net loss per share attributable to common stockholders (in Dollars per share)	($0.23)	($0.18)
Basic and diluted weighted average common shares outstanding (in Shares)	11,796,477	10,926,701
Diagnostics Services [Member]
Revenues:
Diagnostic services	2,287	1,790
Deemed Dividend From Issuing Stock [Member] | Series E Convertivle Preferred Stock [Member]
Other income (expense):
Deemed dividends from issuing Series E convertible preferred stock	($890)
Deemed dividends from issuing Series E convertible preferred stock (in Dollars per share)	($0.08)

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net loss	($1,765)	($1,996)
Unrealized gain (loss) on available-for-sale securities...	4	-5
Total comprehensive loss	($1,761)	($2,001)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net loss	($1,765,000)	($1,996,000)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	90,000	71,000
Non-cash stock compensation	175,000	77,000
Provision for bad debts	50,000	113,000
Changes in assets and liabilities:
Accounts receivable	-182,000	-304,000
Supplies, prepaid expenses and other assets	-19,000	-131,000
Accounts payable, accrued expenses and other	472,000	601,000
Net cash flows from operating activities	-1,179,000	-1,569,000
Investing activities:
Purchase of property and equipment, net of cash received from disposals	-47,000	-4,000
Purchase of available-for-sale investments		-5,061,000
Sale of available-for-sale investments	2,235,000
Net cash flows from investing activities	2,188,000	-5,065,000
Financing activities:
Net proceeds from exercise of common stock warrants		256,000
Payment of accrued issuance costs from issuance of convertible preferred stock		-158,000
Repayments of long-term debt	-43,000	-41,000
Net cash flows from financing activities	4,715,000	57,000
Change in cash and cash equivalents	5,724,000	-6,577,000
Cash and cash equivalents, beginning	1,010,000	12,289,000
Cash and cash equivalents, ending	6,734,000	5,712,000
Non-cash financing activities:
Deemed dividends from issuing Series E convertible preferred stock	890,000
Warrant modifications recognized as Series E offering-related costs	336,000
Reclassification of derivative liability to equity from warrant exercises		135,000
Tenant improvements recognized as deferred rent	164,000
Acqusitions of property and equipment from capital leases and deposits	105,000
Series E Convertible Stock and Common Stock [Member]
Financing activities:
Proceeds from issuance of Series E convertible stock and common stock	4,900,000
Offering-related costs from issuance of Series E convertible stock and common stock.....	($142,000)

Note_1_Overview_and_Background

Note 1 - Overview and Background	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. OVERVIEW AND BACKGROUND
	CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”). In August 2007, we split-off from Acacia and became publicly traded on The Nasdaq Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.
	Description of the Company
	We provide valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care. We specialize in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric healthcare, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. We perform genetic testing utilizing a variety of advanced cytogenomic techniques, including microarray, standardized and customized fluorescent in-situ hybridization (“FISH”) and high resolution karyotyping. We emphasize support of healthcare professionals, to ensure data understanding and communication of results to patients. We deliver high-technology driven answers, with a high degree of assistance for the ordering physician and staff. Our laboratory facilities and corporate headquarters are located in Irvine, California.
	We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and footnotes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2014, as reported by us in our Annual Report on Form 10-K filed with the SEC on March 17, 2015. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of March 31, 2015, and results of operations and cash flows for the interim periods presented. The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the entire year.
	Liquidity and Risks
	We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop new and improve existing commercial diagnostic testing services and related technologies. At March 31, 2015, we had cash, cash equivalents and short-term investments of $8.7 million and anticipate that our cash and cash equivalent balances will be sufficient to meet our cash requirements for at least the next twelve months. In order for us to ultimately achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans.
	Our business operations are also subject to certain risks and uncertainties, including:
		•	market acceptance of our technologies and services;
		•	technological advances that may make our technologies and services obsolete or less competitive;
		•	increases in operating costs, including costs for supplies, personnel and equipment;
		•	variability in third-party reimbursement of our tests;
		•	the availability and cost of capital; and
		•	governmental regulation that may restrict our business.
	Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned technologies or services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the three months ended March 31, 2015 and 2014, net positive revenue adjustments were $127,000 and $144,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. For the quarter ended March 31, 2015, 11% of our revenues were from one customer. No single customer exceeded 10% of revenues for the quarter ended March 31, 2014.
	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statement of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.
	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
	As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	●     Level 1:     Observable market inputs such as quoted prices in active markets;
	●     Level 2:     Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, such as quoted prices for similar assets or liabilities; and
	●     Level 3:     Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
	Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.
	Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.
	Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock on Nasdaq on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):
		For The Three Months
		Ended March 31,
		2015		2014
	Cost of services	$	5	$	4
	Research and development		-		-
	Sales and marketing		26		11
	General and administrative		144		62
	Total non-cash stock compensation	$	175	$	77
	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
		For the Three Months
		Ended March 31,
		2015		2014
	Common stock options		912,109		697,489
	Restricted stock units		623,763		320,220
	Common stock warrants		8,108,905		7,408,905
	Series E preferred stock convertible into common stock		1,257,996		-
	Excluded dilutive securities		10,902,773		8,426,614
	Segments. We have determined that we operate in one segment for financial reporting purposes.
	Recent Accounting Pronouncements. In April 2015, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The guidance requires retrospective application and represents a change in accounting principle. This guidance will be effective for us in the first quarter of 2016, and early adoption is permitted for financial statements that have not been previously issued. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In November 2014, the FASB issued new guidance on determining whether a host contract in a hybrid financial instrument issued in the form of a share is more akin to debt or to equity. This guidance does not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required, but instead clarifies how current GAAP should be interpreted in the evaluation of the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share, thereby reducing existing diversity in practice. The guidance is effective for fiscal years beginning after December 15, 2015 and for interim periods within that fiscal year. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within that fiscal year. We do not expect the adoption of this guidance to have a material effect on our consolidated financial statements.
	In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from generally accepted accounting principles. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in April 2015, the FASB voted to propose a one-year deferral of the effective date of the new guidance. If the proposal is adopted, the new guidance will be effective for us beginning January 1, 2018, with early adoption permitted for annual periods beginning after December 16, 2016. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.
	In April 2014, FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. The changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. We do not believe adoption of this guidance will have a material impact on our consolidated financial statements.
	Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

Note_3_Cash_and_Shortterm_Inve

Note 3 - Cash and Short-term Investments	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents Disclosure [Text Block]	3.      CASH AND SHORT-TERM INVESTMENTS
	As of March 31, 2015, we held $6.7 million in cash and cash equivalents and $2.0 million of short-term investments, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of March 31, 2015 and December 31, 2014 (in thousands):
		31-Mar-15								31-Dec-14
				Unrealized		Unrealized		Fair				Unrealized		Unrealized			Fair
		Cost		Gain		Loss		Value		Cost		Gain		Loss			Value
	Cash and money market securities	$	6,734	$	-	$	-	$	6,734	$	1,010	$	-	$	-		$	1,010
	Corporate bonds		-		-		-		-		1,003		-		-			1,003
	Certificates of deposit		1,995		1		-		1,996		3,230		-		(3	)		3,227
		$	8,729	$	1	$	-	$	8,730	$	5,243	$	-	$	(3	)	$	5,240
	There were no realized gains or losses for the periods ending March 31, 2015 or 2014.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4.     FAIR VALUE MEASUREMENTS
	The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at March 31, 2015 and December 31, 2014 and the classification by level of input within the fair value hierarchy defined above (in thousands):
				Fair Value Measurements
	31-Mar-15	Total		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	5,044	$	5,044	$	-	$	-
	Short-term investments		1,996		-		1,996		-
	Total	$	7,040	$	5,044	$	1,996	$	-
				Fair Value Measurements
	31-Dec-14	Total		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	676	$	676	$	-	$	-
	Short-term investments		4,230		-		4,230		-
	Total	$	4,906	$	676	$	4,230	$	-

Note_5_Secured_Promissory_Note

Note 5 - Secured Promissory Note	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	5.     SECURED PROMISSORY NOTE
	On May 20, 2014 (“Execution Date”), we executed a secured promissory note (the “Note”) with ACC Investment Ltd. in the amount of $350,000, payable in equal amortized payments over a thirty-six month period (the “Term”) from the Execution Date. The Note bears an annual interest rate of 10% and is secured by certain laboratory equipment used in our microarray services business. Legal and other closing costs totaling $22,000 were capitalized with the Note and are being amortized over the Term as interest expense. As of March 31, 2015 and December 31, 2014, the fair value of the Note approximated its carrying value. As of March 31, 2015 and December 31, 2014, components of the Note were as follows (in thousands):
		March 31,			December 31,
		2015			2014
	Carrying value	$	254		$	281
	Unamortized legal and closing costs		(16	)		(18	)
			238			263
	Less- current portion		(115	)		(112	)
	Long-term portion	$	123		$	151

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	6.      STOCKHOLDERS’ EQUITY
	Series A Convertible Preferred Stock and Warrants Financing
	During the fourth quarter of 2012, we issued Series A convertible preferred stock (the “Series A Stock”) and warrants to purchase common stock (the “Series A Warrants”) to certain accredited investors (the “Series A Investors”) for gross proceeds of $2.5 million. During the fourth quarter of 2012 and the first quarter of 2013, all of the Series A Stock converted into 1.25 million shares of common stock, and during 2013, 1.2 million shares of common stock were issued from the exercise of the Series A Warrants, leaving Series A Warrants to purchase 292,817 shares of common stock unexercised as of December 31, 2013. During the three months ended March 31, 2014, Series A Investors exercised Series A Warrants to purchase 124,111 shares of our common stock, resulting in proceeds of $256,000 to us. The Series A Warrants originally had a 5½ year term, price anti-dilution protection and exercise prices of $9.50 (from the first closing) and $2.36 (from the second closing). See below for further discussion of modifications made to the Series A Warrants as a result of the Series D and Series E convertible preferred stock financings executed in December 2013 and February 2015, respectively.
	For as long as the Series A Warrants remain unexercised through their expiration date, we may not sell securities at an effective price per share of less than $4.91 except for certain exempt issuances, unless waivers from the Series A Investors are obtained. Also, prior to a modification we made to the Series A Warrants in June 2014 (the “Modification”) the exercise price of the Series A Warrants and the number of shares of common stock underlying the Series A Warrants were subject to full-ratchet anti-dilution adjustments in the event we issued securities, other than certain exempted issuances, at a price below the then current exercise price of the Series A Warrants.
	We account for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to our own stock. The Series A Warrants issued to Series A Investors contained such provisions prior to the Modification, thus requiring us to treat them as derivative financial instruments, to be recorded at fair value at issuance and subsequently adjusted to fair value at each reporting date, with the corresponding adjustment reflected as a non-operating credit / charge in the consolidated statement of operations. We valued the Series A Warrants at March 31, 2014 using the Monte-Carlo simulation method using the following assumptions: (i) closing stock price and Series A Warrant contractual exercise price; (ii) an expiration term of 4 years; (iii) historical volatilities commensurate with the term of the Series A Warrants of 128.3%; (iv) risk-free interest rates commensurate with the term of the Series A Warrants of 1.3%; and (v) simulated anti-dilution impact assuming various probabilities that we will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise prices during the Series A Warrant terms. For the three months ended March 31, 2014, the result of Series A Warrant exercises as well as these valuation simulations was to value the remaining Series A Warrants held by Series A Investors at $433,000. As a result, warrant derivative gains were insignificant for the period ended March 31, 2014, whereas warrant derivative liabilities from Series A Warrant exercises in the amount of $135,000 were reclassified to stockholders’ equity.
	Series B Convertible Preferred Stock Financing
	On March 19, 2013, we entered into a securities purchase agreement with an existing institutional investor (the “Series B Investor”) to purchase 130,000 shares of common stock at a price of $3.05 per share and approximately 1,610.4 units consisting of, in the aggregate, Series B 6% convertible preferred stock (the “Series B Stock”) and warrants to purchase up to 275,000 shares of common stock at an original exercise price of $3.49 per share (the “Series B Warrants”) in a registered direct offering (the “Series B Financing”) of securities sold off of our existing shelf registration statement on Form S-3 (File No. 333-176372). The Series B Financing closed on March 20, 2013, netting approximately $1.8 million of proceeds to us. The Series B Stock was initially convertible into an aggregate of 528,000 shares of common stock at an initial conversion price of $3.05 per share. During 2013, the Series B Investor converted all of the Series B Stock into common stock.
	The Series B Warrants originally had a 5½ year term as well as a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series B Warrants. The Series B Warrants are not subject to price anti-dilution protection. We also agreed with the Series B Investor pursuant to the Series B Purchase Agreement that, except under certain permitted circumstances, until the time that less than 7.5% of the Series B Warrants remain outstanding, neither we nor our subsidiaries shall issue, or enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Series B Warrants. See below for further discussion of modifications made to the Series B Warrants as a result of the Series E convertible preferred stock financing executed in February 2015.
	Series C Convertible Preferred Stock Financing
	On May 3, 2013, we entered into a securities purchase agreement with two accredited investors (the “Series C Investors”), pursuant to which we sold and issued 1,200 shares of Series C 6% convertible preferred stock (the “Series C Stock”) to the Series C Investors at a purchase price of $1,000 per share in an initial closing that occurred on May 6, 2013 (the “Series C First Closing”) and sold and issued 1,200 additional shares of Series C Stock to the Series C Investors on June 28, 2013 at a purchase price of $1,000 per share after stockholder approval was obtained on June 27, 2013 (the “Series C Second Closing”) (combined, the “Series C Financing”). After certain offering-related costs paid, the net proceeds from the Series C Financing were approximately $2.14 million. During 2013, the Series C Investors converted all 2,400 shares of Series C Stock into 839,864 shares of common stock.
	In addition to the issuance of the Series C Stock, we issued warrants at the Series C First Closing to purchase 491,803 shares of our common stock with an original exercise price of $3.77 per share and at the Series C Second Closing, we issued additional warrants to purchase 491,803 shares of our common stock with an original exercise price of $3.55 per share (collectively, the “Series C Warrants”). The Series C Warrants originally had a 5½ year term, were not exercisable for the first six months following issuance and included a cashless exercise provision, which is only applicable if the common stock underlying the Series C Warrants is not subject to an effective registration statement or otherwise cannot be sold without restriction pursuant to Rule 144. Until all Series C Investors no longer hold Series C Warrants: (i) we may not sell any variable rate securities except for certain exempt issuances; and (ii) if we enter into a subsequent financing on more favorable terms than the Series C Financing, then the agreements between us and the Series C Investors will be amended to include such more favorable terms. In addition, until 7.5% or less of the Series C Warrants remain unexercised, we may not sell any dilutive securities, except for certain exempt issuances. See below for further discussion of modifications made to the Series C Warrants as a result of the Series E convertible preferred stock financing executed in February 2015.
	Series D Convertible Preferred Stock Financing
	On December 20, 2013 (the “Series D Closing”), we closed an underwritten public offering (the “Series D Offering”) and issued 12,000 units of securities to investors, with each unit consisting of: (i) one share of Series D preferred stock (“Series D Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $2.06, which was 72.5% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on December 16, 2013, the date we executed the underwriting agreement (“UA date”); and (ii) one warrant exercisable for 485.4369 shares of our common stock, at an exercise price per share equal to $3.12 (“Series D Warrants”), which was 110% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on the UA date. The shares of common stock underlying the Series D Stock and Series D Warrants were registered on Form S-1 (File No. 333 191221), which was declared effective by the SEC on December 16, 2013. The Series D Stock was immediately convertible and the Series D Warrants were immediately exercisable for shares of common stock and have a term of five years. The Series D Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. In total, there were 5,825,243 shares of common stock issuable upon conversion of the Series D Stock and up to 5,825,243 shares of common stock issuable upon exercise of the Series D Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in net proceeds received by of $10.7 million. From the time of the Series D Closing through the first quarter of 2014, all of the Series D Stock had converted into 5,825,243 shares of common stock. Also as a result of the Series D Offering, the exercise price of the then outstanding Series A Warrants automatically ratcheted down by their terms from their then exercise price of $2.86 per share to an adjusted exercise price of $2.06 per share, and the underlying shares exercisable was automatically increased by 81,910 shares. A registration statement on Form S-3 was filed in order to register these shares for resale as per the terms of our original Series A offering documents. The Series E convertible preferred stock financing below did not impact any of the terms of the Series D Warrants currently outstanding.
	Series E Convertible Preferred Stock Financing
	On February 13, 2015, we and certain accredited institutional pre-existing investors (the “Series E Investors”) entered into a securities purchase agreement (the “Series E Purchase Agreement”), pursuant to which sold 1,541,998 shares common stock at a price of $1.75 per share, 2,201.493 shares of Series E 6% Convertible Preferred Stock (the “Series E Preferred Stock”) and warrants to purchase 700,000 shares of common stock at an exercise price of $1.97 per share, which was the consolidated closing bid price of our common stock on Nasdaq immediately prior to entering into the Series E Purchase Agreement (the “Series E Warrants”, and the transactions contemplated by the Series E Purchase Agreement, the “Series E Financing”). The Series E Preferred Stock and Series E Warrants were sold in a fixed combination consisting of one share of Series E Preferred Stock and a Series E Warrant to purchase approximately 317.965 shares of Common Stock. Each fixed combination of Series E Preferred Stock and Series E Warrants were sold at a price of $1,000. The Series E Preferred Stock sold is convertible into 1,257,996 shares of common stock at an initial conversion price of $1.75 per share. The Series E Preferred Stock is not convertible into greater than 19.99% of our outstanding common stock unless stockholder approval is obtained. The closing under the Series E Purchase Agreement occurred on February 18, 2015 (the “Series E Closing Date”), where we received gross proceeds of $4.9 million from the Series E Investors. After closing-related costs and expenses, net proceeds from the Series E Financing were approximately $4.7 million. Given that the effective conversion price of the Series E Preferred Stock was below the closing market price of our common stock at the time of the Series E Closing Date, we recognized a beneficial conversion feature in the amount of $890,000. Since the Series E Preferred Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.
	The Series E Preferred Stock is non-voting (except to the extent required by law and except for certain consent rights relating to amending the certificate of incorporation or bylaws, and the like), but ranks senior to our common stock with respect to dividends and with respect to distributions upon our deemed dissolution, liquidation or winding-up. Each share of Series E Preferred Stock carries a 6% per annum dividend that will begin accruing six months after the Series E Closing Date and will be payable only in cash. Until the volume weighted average price of our common stock on Nasdaq exceeds 200% of the conversion price of the Series E Preferred Stock for ten consecutive trading days, the Series E Preferred Stock is subject to full ratchet price based anti-dilution protection, subject to certain limitations.
	The Series E Warrants issued have a 5 ½ year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series E Warrants. The Series E Warrants are not exercisable for the first six months following issuance. The Series E Warrants are not subject to price based anti-dilution protection. Subject to the beneficial ownership limitation described below, if, after the one year anniversary of the Series E Closing Date, the volume weighted average price of our common stock on Nasdaq exceeds 200% of the exercise price for ten consecutive trading days, then we have the right to, within one trading day thereafter, call for cancellation of up to 50% of the Series E Warrants for consideration equal to $0.001 per share of common stock underlying the Series E Warrants. We may not exercise our call rights if, among other things, there is no effective registration statement registering the shares of common stock issuable upon exercise of the Series E Warrants or the prospectus contained in the registration statement is not available for the issuance of the shares of common stock issuable upon exercise of the Series E Warrants.
	Pursuant to the terms of the Series E Purchase Agreement, while such Series E Investor holds Series E Preferred Stock and Series E Warrants, we may not enter into an agreement to effect a “Variable Rate Transaction,” which means a transaction in which we: (i) issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of the common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to our business; or (ii) enter into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price. Also, except under certain permitted circumstances: (i) until the later of the date that is six months from the closing or 30 days following the date on which less than 7.5% of the Series E Preferred Stock remains outstanding, we will not issue, or enter into any agreement to issue, any shares of common stock or equivalents thereof; (ii) until the time that less than 7.5% of the Series E Warrants remain outstanding, we may not issue, nor enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Series E Warrants; (iii) until the time that less than 7.5% of the Series E Preferred Stock remains outstanding, we may not issue, nor enter into any agreement to issue, common stock or equivalents thereof at a price below the conversion price of the Series E Preferred Stock unless all shares of common stock underlying the Series E Preferred Stock (taking into consideration the effect of the full adjustment of the anti-dilution provisions from such dilutive issuance) are permitted by certain SEC rules to be issued under the registration statement; (iv) if we issue securities within the six months following the Series E Closing Date under the Series E Purchase Agreement, and subject to the preexisting rights of other security holders, the Series E Investors shall have the right of first refusal to purchase all of the securities on the same terms, conditions and price provided for in the proposed issuance of securities; and (v) we will indemnify the Series E Investors against certain losses resulting from our breach of any of our representations, warranties, or covenants under agreements with the Series E Investors, as well as under certain other circumstances described in the Series E Purchase Agreement.
	The Series E Investors have agreed to be subject to a blocker that (i) would prevent each of their respective common stock ownership at any given time from exceeding 4.99% (which may be increased, but not above 9.99%) of our outstanding common stock; or (ii) would prevent us from issuing any shares of common stock to the Series E Investors upon the conversion of Series E Preferred Stock if the issuance of such shares, when aggregated with all other shares of common stock sold to the Series E Investors under the Series E Purchase Agreement together with all shares of common stock issued upon the conversion of Series E Preferred Stock, would result in the total issuance of common stock to exceed 19.99% of our outstanding common stock, without first obtaining the approval of our stockholders. We agreed to seek stockholder approval at a special stockholders’ meeting to be held on April 28, 2015 for the terms of the Series E Preferred Stock and the issuance and delivery in the aggregate of that number of shares of common stock exceeding 19.99% of the outstanding shares of common stock upon conversion of the Series E Preferred Stock. See further discussion below regarding the results of the special stockholders’ meeting.
	The Series E Financing was effected as a takedown off our shelf registration statement on Form S-3 (File No. 333-198848), which became effective on September 19, 2014, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 13, 2015.
	Private Placement Warrant Financing
	Concurrently with the closing of the Series E Financing, on February 13, 2015, we entered into a separate securities purchase agreement (the “Warrant Purchase Agreement”) with selected accredited institutional pre-existing investors (the “Private Placement Investors”), pursuant to which we agreed to sell to the Private Placement Investors warrants to purchase 1,540,000 shares of Common Stock (the “Private Placement Warrants”, and the transactions contemplated by the Warrant Purchase Agreement, the “Warrant Financing”). In consideration of an aggregate of $1,000, we had agreed to sell the Private Placement Warrants, which would not be issued unless and until our stockholders approved amending our Certificate of Incorporation to increase our authorized common stock to permit the issuance of the common stock issuable upon exercise of the Private Placement Warrants (the “Charter Amendment”). We estimated the fair value of the Private Placement Warrants using the Black-Scholes valuation model to be $1.82 million, which was classified as a warrant subscription payable within additional paid-in capital in our consolidated balance sheet as of March 31, 2015, using the following assumptions: (i) closing stock price and Private Placement Warrants contractual exercise price; (ii) 5.5 year term; (iii) historical volatilities commensurate with the term of the Private Placement Warrants of 113.2%; and (iv) risk-free interest rates commensurate with the term of the Private Placement Warrants of 1.5%. We allocated the proceeds received from the Series E Financing to the Private Placement Warrants based on the relative fair value of the instruments issued to the Series E Investors.
	The special stockholders’ meeting was held on April 28, 2015, in which our stockholders approved the terms of the Series E Preferred Stock financing and the Charter Amendment. As a result, on April 28, 2015, we issued the Private Placement Warrants to the Private Placement Investors.
	Each Private Placement Warrant has an exercise price of $2.167 per share of common stock (subject to adjustment for stock splits and the like), which was 110% of the consolidated closing bid price of our common stock on Nasdaq immediately prior to entering into the Warrant Purchase Agreement, and is exercisable at any time after the six month anniversary of entering into the Warrant Purchase Agreement and on or prior to the close of business on the five year anniversary of the initial exercise date, subject to the beneficial ownership limitation described below. The Private Placement Warrants are not subject to price based anti-dilution protection. If, at the time of exercise of a Private Placement Warrant, there is no effective registration statement registering for resale the shares of common stock issuable upon exercise of the Private Placement Warrant, the holder may exercise the Private Placement Warrant on a cashless basis. When exercised on a cashless basis, a portion of the Private Placement Warrant is cancelled in payment of the purchase price payable in respect of the number of shares of common stock purchasable upon such exercise. Subject to the beneficial ownership limitation described below, if, after the one year anniversary of the date of entering into the Warrant Purchase Agreement, the volume weighted average price of our common stock on Nasdaq exceeds 200% of the Private Placement Warrant exercise price for ten consecutive trading days, then we may, within one trading day thereafter, call for cancellation of up to 50% of the Private Placement Warrants for consideration equal to $0.001 per share of common stock underlying the Private Placement Warrants. We may not exercise our call rights if, among other things, there is no effective registration statement registering for resale the shares of common stock issuable upon exercise of the Private Placement Warrants. Subject to limited exceptions, a holder of Private Placement Warrants will not have the right to exercise any portion of its Private Placement Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (which may be increased, but not above 9.99%) of the number of shares of our common stock outstanding immediately after giving effect to such exercise.
	For as long as the Private Placement Investors hold any Private Placement Warrants, we will not enter into an agreement to affect a “Variable Rate Transaction,” with similar terms and prohibitions described above. We also agreed that, except under certain permitted circumstances until the time that less than 7.5% of the Private Placement Warrants remain outstanding, we will not issue, nor enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Private Placement Warrants.
	Modification of Certain Outstanding Warrants
	In connection with the purchase of the Private Placement Warrants, we modified previously issued and outstanding warrants held by the Private Placement Investors that were issued in connection with the Series A, Series B and Series C financings described above, to (i) reduce the exercise prices thereunder to $1.97, which represents the consolidated closing bid price of our common stock on Nasdaq immediately prior to the date we entered into the Warrant Purchase Agreement; (ii) prohibit the exercise of such modified warrants for a period of six months after the date of the modification; and (iii) extend the exercise period of such modified warrants for an additional six months (such modifications, collectively, the “Warrant Price Modifications”). Separately, we also agreed to a Warrant Price Modification with a holder of Series C Warrants solely in consideration for such holder’s waiver of certain preemptive rights. We estimated the change in fair value of these warrants immediately prior to and immediately subsequently to the Warrant Price Modification to be $336,000, and such amount has been recorded as a non-cash equity offering cost.
	Warrants
	Outstanding warrants to purchase common stock are as follows:
		Shares of Common Stock
		Issuable from Warrants
		Outstanding as of
		March 31,		December 31,		Exercise
		2015		2014		Price		Expiration
	Equity-classified warrants:
	Feb-15		700,000		-	$	1.97	Aug-20
	Jun-14		25,303		25,303	$	2.06	Apr-18
	Dec-13		5,825,243		5,825,243	$	3.12	Dec-18
	Jun-13		491,803		491,803	$	1.97	Jun-19
	May-13		491,803		491,803	$	1.97	May-19
	Mar-13		275,000		275,000	$	1.97	Mar-19
	Oct-12		168,706		168,706	$	1.97	Sep-18
	Apr-11		131,047		131,047	$	21.4	Apr-16
	Total		8,108,905		7,408,905

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7. COMMITMENTS AND CONTINGENCIES
	Executive Severance
	We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (the “Severance Plan”) that affects certain senior management-level employees who are classified as “Section 16 Officers” of the Company.  Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary; (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time.  Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code.  The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors.  In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements.
	Litigation
	On September 30, 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000 in each of the quarters ended March 31, 2015 and 2014, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.
	On February 14, 2011, Relator Michael Strathmann (“Strathmann”) served us with a complaint (“the Complaint”) filed in the Superior Court of the State of California, County of Orange (the “Superior Court”). The Complaint alleged we and our former parent Acacia Research Corporation submitted a false and fraudulent insurance claim to National Union Fire Insurance Company under a Directors and Officers Policy issued to Acacia, in connection with a prior lawsuit that was settled with Nanogen, Inc. The Complaint further alleged that we violated the California Insurance Fraud Prevention Act, and sought penalties and unspecified damages. On May 4, 2011, the Superior Court dismissed the Complaint by ordering that it be stricken for violation of the California Anti-SLAPP statute, which prevents plaintiffs from filing abusive lawsuits against public policy. On June 15, 2011, Strathmann filed a Notice of Appeal with the California Court of Appeal, appealing the granting of our Anti-SLAPP Motion. On October 24, 2012, the California Court of Appeal reversed the Superior Court’s dismissal, finding that the Anti-SLAPP statute was not applicable as a matter of public policy and remanded the case back to the Superior Court. Strathmann filed an Amended Complaint, and we and Acacia filed our Answer to that pleading. A trial was held between June and August of 2014, followed by closing briefs and arguments filed in September and October of 2014. On January 2, 2015, the Superior Court issued a tentative ruling and proposed statement of decision in favor of us, Acacia and Amit Kumar and against all claims of Strathmann. Specifically, the Superior Court determined that it could not find we had any fraudulent intent when we pursued insurance benefits under the National Union Directors and Officers Policy over a decade ago. On March 6, 2015, the Superior Court issued its final Statement of Decision, confirming its tentative ruling that Strathmann failed to prove that we (or any other defendant) had a fraudulent intent when we pursued insurance benefits from National Union. Also on March 6, 2015, the Superior Court entered a Judgment in favor of all defendants and against Strathmann, and ordered that Strathmann’s Complaint be dismissed with prejudice. A Notice of Entry of Judgment was filed with the Superior Court on March 11, 2015.
	On April 23, 2015, we entered into a settlement agreement with Strathmann whereby Strathmann relinquished his rights to further litigate the Complaint or appeal the Judgment. In return, we relinquished our rights to recover certain court costs and to pursue reimbursement of court and legal fees from Strathmann, effectively ending this litigation.
	From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

Note_8_Subsequent_Events

Note 8 - Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	8. SUBSEQUENT EVENTS
	As mentioned above, on April 23, 2015, we entered into a settlement agreement with Strathmann whereby Strathmann relinquished his rights to further litigate the Complaint or appeal the Judgment. In return, we relinquished our rights to recover certain court costs and to pursue reimbursement of court and legal fees from Strathmann, effectively ending this litigation.
	April 28, 2015, our stockholders approved all ballot measures of our special proxy, which included the approval of the Series E Preferred Stock financing and increasing our authorized capital stock from 25 million shares to 50 million shares.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the three months ended March 31, 2015 and 2014, net positive revenue adjustments were $127,000 and $144,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable. For the quarter ended March 31, 2015, 11% of our revenues were from one customer. No single customer exceeded 10% of revenues for the quarter ended March 31, 2014.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with original maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statement of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To-date, no permanent impairment charges have been realized or recorded.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.
	As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	●     Level 1:     Observable market inputs such as quoted prices in active markets;
	●     Level 2:     Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, such as quoted prices for similar assets or liabilities; and
	●     Level 3:     Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
Receivables, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts. For our contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. For our non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances (which reduce revenues) for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.
	Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock on Nasdaq on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented were as follows (in thousands):
		For The Three Months
		Ended March 31,
		2015		2014
	Cost of services	$	5	$	4
	Research and development		-		-
	Sales and marketing		26		11
	General and administrative		144		62
	Total non-cash stock compensation	$	175	$	77
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
		For the Three Months
		Ended March 31,
		2015		2014
	Common stock options		912,109		697,489
	Restricted stock units		623,763		320,220
	Common stock warrants		8,108,905		7,408,905
	Series E preferred stock convertible into common stock		1,257,996		-
	Excluded dilutive securities		10,902,773		8,426,614
Segment Reporting, Policy [Policy Text Block]	Segments. We have determined that we operate in one segment for financial reporting purposes.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements. In April 2015, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The guidance requires retrospective application and represents a change in accounting principle. This guidance will be effective for us in the first quarter of 2016, and early adoption is permitted for financial statements that have not been previously issued. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In November 2014, the FASB issued new guidance on determining whether a host contract in a hybrid financial instrument issued in the form of a share is more akin to debt or to equity. This guidance does not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required, but instead clarifies how current GAAP should be interpreted in the evaluation of the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share, thereby reducing existing diversity in practice. The guidance is effective for fiscal years beginning after December 15, 2015 and for interim periods within that fiscal year. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within that fiscal year. We do not expect the adoption of this guidance to have a material effect on our consolidated financial statements.
	In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from generally accepted accounting principles. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. As originally issued, the new revenue recognition standard would be effective for us beginning January 1, 2017. However, in April 2015, the FASB voted to propose a one-year deferral of the effective date of the new guidance. If the proposal is adopted, the new guidance will be effective for us beginning January 1, 2018, with early adoption permitted for annual periods beginning after December 16, 2016. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.
	In April 2014, FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. The changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. We do not believe adoption of this guidance will have a material impact on our consolidated financial statements.
Reclassification, Policy [Policy Text Block]	Reclassifications. Certain prior period amounts have been reclassified to conform to the current period presentation.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		For The Three Months
		Ended March 31,
		2015		2014
	Cost of services	$	5	$	4
	Research and development		-		-
	Sales and marketing		26		11
	General and administrative		144		62
	Total non-cash stock compensation	$	175	$	77
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		For the Three Months
		Ended March 31,
		2015		2014
	Common stock options		912,109		697,489
	Restricted stock units		623,763		320,220
	Common stock warrants		8,108,905		7,408,905
	Series E preferred stock convertible into common stock		1,257,996		-
	Excluded dilutive securities		10,902,773		8,426,614

Note_3_Cash_and_Shortterm_Inve1

Note 3 - Cash and Short-term Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments [Table Text Block]		31-Mar-15								31-Dec-14
				Unrealized		Unrealized		Fair				Unrealized		Unrealized			Fair
		Cost		Gain		Loss		Value		Cost		Gain		Loss			Value
	Cash and money market securities	$	6,734	$	-	$	-	$	6,734	$	1,010	$	-	$	-		$	1,010
	Corporate bonds		-		-		-		-		1,003		-		-			1,003
	Certificates of deposit		1,995		1		-		1,996		3,230		-		(3	)		3,227
		$	8,729	$	1	$	-	$	8,730	$	5,243	$	-	$	(3	)	$	5,240

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]				Fair Value Measurements
	31-Mar-15	Total		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	5,044	$	5,044	$	-	$	-
	Short-term investments		1,996		-		1,996		-
	Total	$	7,040	$	5,044	$	1,996	$	-
				Fair Value Measurements
	31-Dec-14	Total		Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	676	$	676	$	-	$	-
	Short-term investments		4,230		-		4,230		-
	Total	$	4,906	$	676	$	4,230	$	-

Note_5_Secured_Promissory_Note1

Note 5 - Secured Promissory Note (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		March 31,			December 31,
		2015			2014
	Carrying value	$	254		$	281
	Unamortized legal and closing costs		(16	)		(18	)
			238			263
	Less- current portion		(115	)		(112	)
	Long-term portion	$	123		$	151

Note_6_Stockholders_Equity_Tab

Note 6 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Shares of Common Stock
		Issuable from Warrants
		Outstanding as of
		March 31,		December 31,		Exercise
		2015		2014		Price		Expiration
	Equity-classified warrants:
	Feb-15		700,000		-	$	1.97	Aug-20
	Jun-14		25,303		25,303	$	2.06	Apr-18
	Dec-13		5,825,243		5,825,243	$	3.12	Dec-18
	Jun-13		491,803		491,803	$	1.97	Jun-19
	May-13		491,803		491,803	$	1.97	May-19
	Mar-13		275,000		275,000	$	1.97	Mar-19
	Oct-12		168,706		168,706	$	1.97	Sep-18
	Apr-11		131,047		131,047	$	21.4	Apr-16
	Total		8,108,905		7,408,905

Note_1_Overview_and_Background1

Note 1 - Overview and Background (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Disclosure Text Block [Abstract]
Cash, Cash Equivalents, and Short-term Investments	$8,729	$5,243

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%
Net Revenue Adjustments (in Dollars)	$127,000	$144,000
Number of Customers	1	0
Restricted Stock Units (RSUs) [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Number of Reportable Segments	1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	11.00%	10.00%
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Equity Method Investment, Ownership Percentage	20.00%
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Equity Method Investment, Ownership Percentage	50.00%

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Stock-Based Compensation by Functional Expense Categories (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$175	$77
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	5	4
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	26	11
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$144	$62

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Anti-Dilutive Securities	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	10,902,773	8,426,614
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	912,109	697,489
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	623,763	320,220
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	8,108,905	7,408,905
Series E Convertivle Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,257,996

Note_3_Cash_and_Shortterm_Inve2

Note 3 - Cash and Short-term Investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents, at Carrying Value	$6,734	$1,010
Short-term Investments	$1,996	$4,230

Note_3_Cash_and_Shortterm_Inve3

Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	$8,729	$5,243
Cash and Cash Equivalents, Unrealized Loss	1	-3
Cash and Cash Equivalents, Fair Value	8,730	5,240
	1	-3
Cash and Money Market Securities [Member]
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	6,734	1,010
Cash and Cash Equivalents, Fair Value	6,734	1,010
Corporate Bonds [Member]
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost		1,003
Cash and Cash Equivalents, Fair Value		1,003
Certificates of Deposit [Member]
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	1,995	3,230
Cash and Cash Equivalents, Unrealized Loss	1	-3
Cash and Cash Equivalents, Fair Value	1,996	3,227
	$1	($3)

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Financial Assets Measured on Recurring Basis (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Assets:
Cash equivalents	$5,044	$676
Short-term investments	1,996	4,230
Total	8,729	5,243
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash equivalents	5,044	676
Total	5,044	676
Fair Value, Inputs, Level 2 [Member]
Assets:
Short-term investments	1,996	4,230
Total	$1,996	$4,230

Note_5_Secured_Promissory_Note2

Note 5 - Secured Promissory Note (Details) (Secured Debt [Member], USD $)	3 Months Ended
	Mar. 31, 2015	20-May-14
Secured Debt [Member]
Note 5 - Secured Promissory Note (Details) [Line Items]
Debt Instrument, Face Amount		$350,000
Debt Instrument, Term	36 months
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Issuance Cost	$22,000

Note_5_Secured_Promissory_Note3

Note 5 - Secured Promissory Note (Details) - Components of Secured Promissory Note (Secured Debt [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Secured Debt [Member]
Note 5 - Secured Promissory Note (Details) - Components of Secured Promissory Note [Line Items]
Carrying value	$254	$281
Unamortized legal and closing costs	-16	-18
	238	263
Less- current portion	-115	-112
Long-term portion	$123	$151

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

Mar. 31, 2014

Feb. 13, 2015

Mar. 31, 2015

Dec. 31, 2012

Dec. 31, 2013

Mar. 19, 2013

Jun. 28, 2013

Mar. 31, 2013

3-May-13

Dec. 31, 2013

Dec. 31, 2013

Dec. 20, 2013

Feb. 18, 2015

Note 6 - Stockholders' Equity (Details) [Line Items]

Proceeds from Warrant Exercises (in Dollars)

$256,000

Warrant Liability Reclassified to Stockholders Equity (in Dollars)

135,000

Percentage of Closing Bid Price

72.50%

First Closing [Member] | Series A Warrants [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$9.50

Second Closing [Member] | Series A Warrants [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$2.36

Before Adjustment [Member] | Series A Warrants [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$2.86

Fixed Combination [Member] | Series E Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Share Price (in Dollars per share)

$1,000

Modification of Certain Outstanding Warrants [Member] | Private Placement [Member] | Warrant Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$1.97

Private Placement [Member] | Common Stock [Member] | Private Placement Investors [Member] | Warrant Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,540,000

Private Placement [Member] | Warrant Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$2.17

Fair Value Assumptions, Expected Term

5 years 6 months

Fair Value Assumptions, Expected Volatility Rate

113.20%

Fair Value Assumptions, Risk Free Interest Rate

1.50%

Percentage of Volume Weighted Average Price of Common Stock

200.00%

Conversion Price Consecutive Trading Days

10

Percentage of Warrants Cancelled Threshold

50.00%

Price Per Share of Common Stock (in Dollars per share)

$0.00

Maximum Common Stock Ownership by Investor

4.99%

Potential Maximum Common Stock Ownership by Investor

9.99%

Proceeds from Issuance of Warrants (in Dollars)

1,000

Warrants Not Settleable in Cash, Fair Value Disclosure (in Dollars)

1,820,000

Percentage of Closing Bid Price of Common Stock

110.00%

Percentage of Warrants Outstanding Threshold

7.50%

Fair Value Adjustment of Warrants (in Dollars)

336,000

Series A Warrants [Member] | Series A Convertible Preferred Stock [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)

2,500,000

Series A Warrants [Member] | Minimum [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Share Price (in Dollars per share)

$4.91

Series A Warrants [Member] | Maximum [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Warrant Liability Reclassified to Stockholders Equity (in Dollars)

135,000

Series A Warrants [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Stock Issued During Period, Shares, Warrant Exercised

124,111

1,200,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

81,910

292,817

292,817

292,817

Proceeds from Warrant Exercises (in Dollars)

256,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$2.06

Fair Value Assumptions, Expected Term

4 years

Fair Value Assumptions, Expected Volatility Rate

128.30%

Fair Value Assumptions, Risk Free Interest Rate

1.30%

Warrants and Rights Outstanding (in Dollars)

433,000

Series B Warrants [Member] | Maximum [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Warrant Agreement, Percentage of Warrants Outstanding Threshold

7.50%

Series B Warrants [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

275,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

3.49

Series C Warrant [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

491,803

491,803

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$3.55

$3.77

Warrant Agreement, Percentage of Warrants Outstanding Threshold

7.50%

Series D Warrant [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Convertible Preferred Stock, Shares Issued upon Conversion

5,825,243

5,825,243

5,825,243

Series E Warrant [Member] | Common Stock [Member] | Series E Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

700,000

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

317.965

Series E Warrant [Member] | Series E Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Percentage of Volume Weighted Average Price of Common Stock

200.00%

Conversion Price Consecutive Trading Days

10

Percentage of Warrants Cancelled Threshold

50.00%

Price Per Share of Common Stock (in Dollars per share)

$0.00

Common Stock [Member] | Series E 6% Convertible Preferred Stock [Member] | Series E Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Convertible Preferred Stock, Shares Issued upon Conversion

1,257,996

Series A Convertible Preferred Stock [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Conversion of Stock, Shares Converted

1,250,000

Series B Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Stock Issued During Period, Shares, New Issues

130,000

Sale of Stock, Price Per Share (in Dollars per share)

3.05

Series B Convertible Preferred Stock [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Stock Issued During Period, Shares, New Issues

1,610.40

Proceeds from Issuance of Convertible Preferred Stock (in Dollars)

1,800,000

Convertible Preferred Stock, Shares Issued upon Conversion

528,000

Convertible Preferred Stock, Conversion Price (in Dollars per share)

3.05

Series C Convertible Preferred Stock [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Conversion of Stock, Shares Converted

2,400

Share Price (in Dollars per share)

$1,000

$1,000

Stock Issued During Period, Shares, New Issues

1,200

1,200

Proceeds from Issuance of Convertible Preferred Stock (in Dollars)

2,140,000

Conversion of Stock, Shares Issued

839,864

Series D Convertible Preferred Stock [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

485.4369

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$3.12

Stock Issued During Period, Shares, New Issues

12,000

Sale of Stock, Price Per Share (in Dollars per share)

1,000

1,000

$1,000

Convertible Preferred Stock, Shares Issued upon Conversion

5,825,243

5,825,243

5,825,243

Conversion of Stock, Shares Issued

5,825,243

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$2.06

Warrants, Term

5 years

Series E 6% Convertible Preferred Stock [Member] | Series E Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$1.97

Stock Issued During Period, Shares, New Issues

2,201.49

Proceeds from Issuance of Convertible Preferred Stock (in Dollars)

4,900,000

Maximum Percentage of Convertible Stock into Outstanding Common Stock

19.99%

Proceeds from Issuance of Convertible Preferred Stock, Net (in Dollars)

4,700,000

Preferred Stock, Dividend Rate, Percentage

6.00%

Percentage of Volume Weighted Average Price of Common Stock

200.00%

Conversion Price Consecutive Trading Days

10

Percentage of Preferred Stock OutstandingThreshold

7.50%

Series E 6% Convertible Preferred Stock [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)

890,000

Series E Purchase Agreement [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Share Price (in Dollars per share)

$1.75

Stock Issued During Period, Shares, New Issues

1,541,998

Convertible Preferred Stock, Conversion Price (in Dollars per share)

$1.75

Maximum Common Stock Ownership by Investor

4.99%

Potential Maximum Common Stock Ownership by Investor

9.99%

Net [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

Proceeds from Issuance of Convertible Preferred Stock (in Dollars)

$10,700,000

Note_6_Stockholders_Equity_Det1

Note 6 - Stockholders' Equity (Details) - Outstanding Warrants (USD $)	Mar. 31, 2015	Dec. 31, 2014
February 2015 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	1.97
February 2015 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	700,000
June 2014 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	2.06
June 2014 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	25,303	25,303
December 2013 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	3.12
December 2013 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	5,825,243	5,825,243
June 2013 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	1.97
June 2013 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	491,803	491,803
May 2013 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	1.97
May 2013 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	491,803	491,803
March 2013 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	1.97
March 2013 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	275,000	275,000
October 2012 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	1.97
October 2012 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	168,706	168,706
April 2011 [Member] | Minimum [Member]
Equity-classified warrants:
Exercise Price (in Dollars per share)	21.4
April 2011 [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	131,047	131,047
Equity-classified Warrants [Member]
Equity-classified warrants:
Issuable from Warrants outstanding	8,108,905	7,408,905

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Litigation Settlement Percentage	12.50%
Maximum Annual Litigation Payment	$1,500,000
Minimum Quarterly Litigation Payment	25,000
Royalty Expense	$25,000	$25,000

Note_8_Subsequent_Events_Detai

Note 8 - Subsequent Events (Details)	Mar. 31, 2015	Dec. 31, 2014	Apr. 28, 2015	Apr. 27, 2015
In Millions, unless otherwise specified
Note 8 - Subsequent Events (Details) [Line Items]
Common Stock, Shares Authorized	25	25
Subsequent Event [Member]
Note 8 - Subsequent Events (Details) [Line Items]
Common Stock, Shares Authorized			50	25